Side-by-side comparison of AI visibility scores, market position, and capabilities
Shelton CT electrical products and utility solutions (NYSE: HUBB) ~$5.6B FY2024 revenue (+4.8%); grid modernization transformers, data center power distribution, double-digit op profit growth competing with Eaton and ABB.
Hubbell Incorporated is a Shelton, Connecticut-based electrical products and utility solutions company — publicly traded on the New York Stock Exchange (NYSE: HUBB) as an S&P 500 Industrials component — manufacturing and selling wiring devices, industrial electrical equipment, power systems, data center power distribution, and utility grid automation products through approximately 18,000 employees in manufacturing plants across the United States, Canada, and internationally. In fiscal year 2024, Hubbell reported full-year revenue of approximately $5.6 billion (+4.76% year-over-year), with double-digit growth in operating profit, earnings per share, and free cash flow — demonstrating the operational leverage of Hubbell's product mix as demand for electrical infrastructure (grid modernization, data center power distribution, EV charging) drove volume into Hubbell's higher-margin product lines. CEO Gerben Bakker has positioned Hubbell's two segments for distinct growth vectors: Hubbell Electrical Products (wiring devices, commercial and industrial electrical distribution components, residential and commercial electrical boxes and conduit) and Utility Solutions (electric utility transmission and distribution equipment — transformers, meters, grid automation relays, switches, and padmount transformers for underground distribution). The Utility Solutions segment's grid automation and transformer products benefit directly from grid modernization investment driven by state renewable portfolio standards, EV load integration requirements, and federal infrastructure funding through the Inflation Reduction Act grid resilience grants.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.